Expert Opinion on the First-Line Management of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in India: The Role of Faricimab

TL;DR

This paper discusses the use of faricimab as a first-line treatment for eye conditions like neovascular age-related macular degeneration and diabetic macular edema in India.

Contribution

The paper presents expert strategies for integrating faricimab as a first-line treatment for nAMD and DME, emphasizing its clinical value and durability.

Findings

Faricimab is considered a valuable first-line treatment for nAMD and DME due to its dual inhibition strategy.

Experts recommend individualized dosing and treatment sequencing to achieve durable disease control.

Faricimab offers improved vascular stability and treatment response durability in routine clinical practice.

Abstract

This expert opinion article summarizes deliberations from a focused panel discussion involving nine retina specialists on the clinical utility of faricimab in managing neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The discussion explored evolving understanding of the multifactorial disease mechanisms, including pathways beyond vascular endothelial growth factor-A, and the rationale for dual inhibition strategies. Experts shared their clinical perspectives on faricimab use in diverse patient profiles, treatment sequencing, and individualized dosing approaches to achieve durable disease control. Practical considerations around early initiation, optimization of treatment intervals, and real-world applicability were also discussed. The insights highlight expert-derived strategies for integrating faricimab as a first-line treatment into clinical practice, emphasizing its role in achieving vascular stability and the improved durability of treatment response. Overall, the panel concluded that faricimab represents a clinically valuable first-line therapeutic option for nAMD and DME, enabling individualized, durable disease control in routine practice.